COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #143 of 264
9/21 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gentry et al., Lancet Rheumatology, doi:10.1016/S2665-9913(20)30305-2 (Peer Reviewed)
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Source   PDF   Share   Tweet
Retrospective patients with rheumatologic conditions showing zero of 10,703 COVID-19 deaths for HCQ patients versus 7 of 21,406 propensity matched control patients (not statistically significant). The average age of HCQ patients is slightly lower 64.8 versus 65.4 control.
COVID-19 cases OR 0.79, p=0.27. There are several significant differences in the propensity matched patients that could affect results, e.g., 20.9% SLE versus 24.7%.

Gentry et al., 9/21/2020, retrospective, database analysis, USA, North America, peer-reviewed, 6 authors.
risk of death, 91.3% lower, RR 0.09, p = 0.10, treatment 0 of 10703 (0.0%), control 7 of 21406 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), COVID-19 mortality within all patients.
risk of death, 90.7% lower, RR 0.09, p = 0.19, treatment 0 of 31 (0.0%), control 7 of 78 (9.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), mortality for infected patients.
risk of COVID-19 case, 20.9% lower, RR 0.79, p = 0.27, treatment 31 of 10703 (0.3%), control 78 of 21406 (0.4%), odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.